Shandong Keyuan Pharmaceutical Co. Ltd. A (301281) — Capital Reinvestment Ratio

Latest as of December 2023: 1.89x

Shandong Keyuan Pharmaceutical Co. Ltd. A (301281) has a Capital Reinvestment Ratio of 1.89x as of December 2023, meaning it reinvests 2% of its operating cash flow (CN¥37.03 Million) in capital expenditures (CN¥70.15 Million). Check how tangible is Shandong Keyuan Pharmaceutical Co. Ltd. 's equity to evaluate the tangible quality of the company's equity base.

Capital Reinvestment Ratio

1.89x
Capex / Operating Cash Flow

Operating Cash Flow

CN¥37.03 Million
CNY

Capital Expenditures

CN¥70.15 Million
CNY

Data as of

Dec 2023
Most recent filing

Shandong Keyuan Pharmaceutical Co. Ltd. A Capital Reinvestment Ratio (2021–2023)

This chart tracks Shandong Keyuan Pharmaceutical Co. Ltd. A's Capital Reinvestment Ratio across 3 annual periods. For the full cash flow conversion analysis, see 301281 cash flow metrics.

Annual Capital Reinvestment Ratio for Shandong Keyuan Pharmaceutical Co. Ltd. A (2021–2023)

Year-by-year Capital Reinvestment Ratio for Shandong Keyuan Pharmaceutical Co. Ltd. A from 2021 to 2023. See 301281 cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.

Year Reinvestment Ratio Operating CF (CNY) Capital Expenditures YoY Change
2023 1.89x CN¥37.03 Million CN¥70.15 Million ▲ +605.5%
2022 0.27x CN¥115.86 Million CN¥31.11 Million ▼ -30.8%
2021 0.39x CN¥52.02 Million CN¥20.19 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow